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Mitochondrial apoptosisIn Jurkat T cell clone (JT/Neo), G2/M arrest, apoptotic sub-G1 peak, mitochondrial membrane potential (Δψm)
loss, and TUNEL-positive DNA fragmentation were induced following exposure to 17α-estradiol (17α-E2),
whereas none of these events (except for G2/M arrest) were induced in Jurkat cells overexpressing Bcl-2
(JT/Bcl-2). Under these conditions, phosphorylation at Thr161 and dephosphorylation at Tyr15 of Cdk1,
upregulation of cyclin B1 level, histone H1 phosphorylation, Cdc25C phosphorylation at Thr-48, Bcl-2 phos-
phorylation at Thr-56 and Ser-70, Mcl-1 phosphorylation, and Bim phosphorylation were detected in the
presence of Bcl-2 overexpression. However, the 17α-E2-induced upregulation of Bak levels, activation of Bak,
activation of caspase-3, and PARP degradation were abrogated by Bcl-2 overexpression. In the presence of the
G1/S blocking agent hydroxyurea, 17α-E2 failed to induce G2/M arrest and all apoptotic events including Cdk1
activation and phosphorylation of Bcl-2, Mcl-1 and Bim. The 17α-E2-induced phosphorylation of Bcl-2 family
proteins andmitochondrial apoptotic eventswere suppressed by a Cdk1 inhibitor but not by aurora A and aurora
B kinase inhibitors. Immunoﬂuorescence microscopic analysis showed that an aberrant bipolar microtubule
array, incomplete chromosome congression at themetaphase plate, and prometaphase arrest, whichwas revers-
ible, were the underlying factors for 17α-E2-induced mitotic arrest. The in vitro microtubule polymerization
assay showed that 17α-E2 could directly inhibit microtubule formation. These results show that the apoptogenic
activity of 17α-E2was due to the impairedmitotic spindle assembly causing prometaphase arrest and prolonged
Cdk1 activation, the phosphorylation of Bcl-2, Mcl-1 and Bim, and the activation of Bak and mitochondria-
dependent caspase cascade.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The biological activity of estrogens is mediated by three different
mechanisms: the intracellular estrogen receptor (ER)-mediated ge-
nomic mechanism; the plasma membrane ER-mediated nongenomic
mechanism associated with cell signaling pathways; and an ER-
independent mechanism [1,2]. The ER-mediated genomic action of
estrogens is elicited by binding with the nuclear receptor estrogen
receptor α (ERα) and β (ERβ), and the subsequent transcriptional
regulationof gene expression [3]. TheplasmamembraneER-mediated ac-
tion of estrogens rapidly triggers second messenger signaling events, in
which activated ERs do not directly alter the expression of target genes.
The ER-independent action of estrogens is induced at pharmacologicalgy, School of Life Science and
k National University, Daegu
x: +82 53 955 5522.
l rights reserved.concentrations (in themicromolar range) and is not blocked by ER antag-
onists such as ICI 182,780 or tamoxifen [4].
17β-Estradiol (17β-E2), the predominant and most biologically
active estrogen, at physiological concentrations (in the nanomolar
range) is known to reduce neuronal apoptosis in various in vivo and
in vitro neurodegenerative conditions [5,6]. However, 17β-E2 is also
known to exert pro-apoptotic effects on bone-resorbing osteoclasts
and thymocytes, suggesting that the apoptotic regulatory activity of
17β-E2 may differ depending upon the target cell types [7,8]. In con-
trast, 17α-estradiol (17α-E2), which is a stereoisomer of 17β-E2 and fails
to interact effectively with the ER, has long been considered hormonally
inactive; thus, little attention has been given to its roles. Recently, it has
been shown that 17α-E2 is as potent as 17β-E2 in protecting neurons
from toxic stress conditions [9]. This neuroprotective action of 17α-E2
is exerted through ER-independent nongenomic mechanisms that in-
clude the prevention of oxidative stress, stabilization of the membrane,
and retention of mitochondrial integrity. Therefore, the clinical applica-
tion of 17α-E2, as a neuroprotective therapeutic agent, is expected to
2221C.R. Han et al. / Biochimica et Biophysica Acta 1833 (2013) 2220–2232be more beneﬁcial than 17β-E2, in that 17α-E2 possesses low genomic
effects and equipotent nongenomic effects compared with 17β-E2, thus
avoiding the adverse effects of 17β-E2.
In relation to the cytoprotection of 17β-E2 toward malignant
tumor cells, several studies have indicated that 17β-E2 establishes a
survival advantage in an ER-dependent manner, which then increases
the risk of hormone-responsive breast or endometrial cancers [10,11].
In ER-positive breast cancer cells, a physiological dose of 17β-E2 can
suppress apoptosis through the plasma membrane ER-dependent
Ras signaling pathway [11]. In addition, 17β-E2 (50 μM) appears to
inhibit the proliferation of breast cancer cells through microtubule
disruption, irrespective of the presence of ERs [12]. In human leuke-
mia cell lines, 17β-E2 has exhibited IC50 values ranging between
25 μM and >100 μM [13]. After exposure to 17β-E2 (400 μM), Jurkat
T cells undergo apoptosis through suppression of Bcl-2 and cyclin A
levels [14]. These data suggest that 17β-E2 stimulates cancer cell survival
and proliferation at a physiological dose through an ER-dependent
mechanism, whereas 17β-E2 inhibits cancer cell proliferation at a
pharmacological dose by inducing apoptosis or microtubule disrup-
tion independent of the ER. An endogenous metabolite of 17β-E2,
2-methoxyestradiol (2-MeO-E2) has been investigated as a promising
anticancer drug candidate [15]. The anticancer actions of 2-MeO-E2 at
pharmacological concentrations are exerted by inducing apoptosis,
arresting cell growth at the G1/S boundary and/or G2/M boundary, or
inhibiting angiogenesis. The 2-MeO-E2-induced apoptosis in tumor
cells appears to be mediated by several different mechanisms, such as
the upregulation of p53 and p21, down-regulation of Bcl-2, phosphory-
lation of Bcl-2 and Bcl-xL, accumulation of reactive oxygen species
(ROS), activation of c-Jun N-terminal kinase (JNK), and mitochondrial
cytochrome c release in an ER-independent manner [16–18]. However,
little information is known regarding the effect of 17α-E2 on tumor cell
proliferation and apoptosis.
Previously, we have shown that a pharmacological dose (5–
10 μM) of 17α-E2, but not 17β-E2, can induce apoptosis in human
acute leukemia Jurkat T cells, which are known to not express ERs
[19], via a mitochondria-dependent caspase cascade activation [20].
The 17α-E2-induced apoptosis occurs mainly in G2/M-arrested cells
and is accompanied by an increase in Bcl-2 phosphorylation at
Thr-56 [20], a known site that can be phosphorylated by the Cdk1/
cyclin B1 kinase during G2/M phase [21]. In the present study, to elu-
cidate how 17α-E2 arrests cell cycle progression at the G2/M phase
and how 17α-E2-induced G2/M arrest is related to the activation of
mitochondria-dependent apoptotic events, we investigated the effect
of 17α-E2 (5–10 μM) on microtubule network organization, Cdk1
activation, and the pro-apoptotic behavior of Bcl-2 family proteins,
which leads to mitochondrial damage, using Jurkat T cell clones stably
transfected with an empty vector (JT/Neo) or a Bcl-2 expression vec-
tor (JT/Bcl-2).
2. Materials and methods
2.1. Reagents, antibodies, and cells
17α-E2, 17β-E2, hydroxyurea, and an anti-α-tubulin antibody were
purchased from Sigma Chemical (St. Louis, MO, USA). The broad-
range caspase inhibitor z-VAD-fmk was obtained from Calbiochem
(San Diego, CA, USA). An ECL Western blotting kit was purchased
from Amersham (Arlington Heights, IL, USA). The anti-caspase-3 anti-
body was purchased from Pharmingen (San Diego, CA, USA), and
anti-poly (ADP-ribose) polymerase (PARP), anti-Bak, anti-Bax, anti-
Bim, anti-Bcl-2, anti-Bcl-xL, anti-Mcl-1, anti-Cdk1, anti-cyclin B1, anti-
aurora A kinase (ARK1), anti-histone H1, anti-p-histone H3 (Ser-10),
and anti-histone H3 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The anti-caspase-8, anti-caspase-9,
anti-p-Cdk1 (Tyr-15), anti-p-Cdk1 (Thr-161), anti-p-Cdc25C (Thr-48),
anti-Cdc25C, anti-p-Bcl-2 (Thr-56), anti-p-Bcl-2 (Ser-70), anti-p-Mcl-1(Ser-159/Thr-163), anti-p-aurora A kinase (Thr-288), anti-Bad and
anti-Bid antibodies were purchased from Cell Signaling Technology
(Beverly, MA, USA), and anti-p-histone H1 was purchased from
Upstate Biotechnology (Lake Placid, NY, USA). The anti-Bak (Ab-1)
and anti-Bax (6A7) antibodies were obtained from Calbiochem (San
Diego, CA, USA); anti-p-Bcl-xL (Ser-62) was obtained from Invitrogen
(Carlsbad, CA, USA). The Cdk1 inhibitor RO3306 was purchased from
Tocris Bioscience (Ellisville, MO, USA), and the aurora A kinase inhibitor
MLN8237 and aurora B kinase inhibitor AZD1152-HQPA were obtained
from Selleck (Huston, TX, USA).
Human acute leukemia Jurkat T cell clones, transfected with a Bcl-2
expression vector (JT/Bcl-2) or an empty vector (JT/Neo) and with a
Bcl-xL expression vector (J/Bcl-xL) or an empty vector (J/Neo), were
supplied by Dr. Dennis Taub (Gerontology Research Center, NIA/NIH,
Baltimore, MD, USA). Jurkat T cells were maintained in RPMI 1640
medium (Life Technologies, Gaithersburg, MD, USA) containing 10%
FBS (UBI, Lake Placid, NY, USA), 20 mM HEPES (pH 7.0), 5 × 10−5 M
β-mercaptoethanol and 100 μg/ml gentamycin. For the culture of both
JT/Bcl-2 and JT/Neo cells, G418 (A.G. Scientiﬁc Inc., San Diego, CA,
USA) was added to the medium at a concentration of 400 μg/ml. To
investigate the effect of the aurora A kinase inhibitor MLN8237 [22],
the aurora B kinase inhibitor AZD1152-HQPA [23], and the Cdk1 inhib-
itor RO3306 [24] on 17α-E2-induced apoptotic events, JT/Neo cellswere
pretreatedwith the individual inhibitors for 2 h prior to treatmentwith
17α-E2 for 20 h.
2.2. Flow cytometric analyses
Flow cytometric analysis for the cell cycle of Jurkat T cells exposed
to 17α-E2 was performed as described elsewhere [25]. Changes in the
mitochondrial membrane potential (Δψm) following treatment with
17α-E2 weremeasured after stainingwith 3,3′-dihexyloxacarbocyanine
iodide (DiOC6) [26]. After treatment with 17α-E2, the cells were
harvested and incubated with PBS containing 50 nM DiOC6 for 15 min
at 37 °C prior to ﬂow cytometric analysis.
Bak and Bax activation in Jurkat T cells following treatment with
17α-E2 was measured using ﬂow cytometry as previously described
[27]. Brieﬂy, the cells (1 × 106) were washed with PBS and ﬁxed in
PBS/1.0% paraformaldehyde on ice for 30 min. The cells were then
washed three times in staining buffer (PBS, 500 μg/ml digitonin).
Staining with conformation-speciﬁc antibodies against Bak (Ab-1)
and Bax (6A7) was performed with the proper dilution of individual
antibodies in staining buffer. Then, the cells were washed and re-
suspended in staining buffer containing Alexaﬂuor 488-labeled goat
anti-mouse IgG. Bak and Bax conformational changes were measured
using ﬂow cytometry.
2.3. TdT-mediated dUTP nick-end labeling (TUNEL) assay
Jurkat T cells treated with 17α-E2 were adhered onto glass cover
slips pretreated with 2% aminopropyltriethoxy-silane for 30 min in a
humidiﬁed chamber as previously described [27]. The cells were then
subjected to ﬂuorescence-terminal dUTP nick-end labeling (TUNEL)
using the in situ cell death detection kit (Roche Applied Science, Basel,
Switzerland). The cells were then stained with 4′,6-diamidino-2-
phenylindole (DAPI) to label the nuclei and examined under the LSM
700 confocal laser scanning microscope (Carl Zeiss MicroImaging
GmbH, Germany).
2.4. Immunoﬂuorescence microscopy
Human Jurkat T cells were adhered onto glass cover slips pretreated
with 2% aminopropyltriethoxysilane for 30 min in a humidiﬁed cham-
ber as previously described [27] and ﬁxed with cold methanol for
3 min. The cells were rinsed four times with cold PBS containing
0.5% Triton X-100, and blocked with 10% goat serum for 30 min. The
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goat-polyclonal anti-lamin B (1:200) overnight at 4 °C. For detection,
the cells were treated with Alexaﬂuor 488-labeled goat anti-mouse IgG
(1:1000) or Alexaﬂuor 568-labeled donkey anti-goat IgG for 1 h at
room temperature. Images were visualized and photographed using the
LSM 700 confocal laser scanning microscope (Carl Zeiss MicroImaging
GmbH, Germany).2.5. Preparation of cell lysates and Western blot analyses
Cell lysates were prepared by suspending 5 × 106 Jurkat T cells in
300 μl of the lysis buffer (137 mM NaCl, 15 mM EGTA, 1 mM sodium
orthovanadate, 15 mM MgCl2, 0.1% Triton X-100, 25 mM MOPS,
1 mM PMSF, and 2.5 μg/ml proteinase inhibitor E-64, pH 7.2). The
cells were disrupted by sonication and extracted for 30 min at 4 °C. An
equivalent amount of protein lysate (20–30 μg) was electrophoresed
on a 4–12% SDS gradient polyacrylamide gel with 3-(N-morpholino)
propanesulfonic acid buffer. The proteins were electrotransferred to
Immobilon-P membranes (Millipore Corporation, Bedford, MA, USA).
Protein detection was performed with an ECL Western blotting kit
(Amersham, Heights, IL, USA), according to the manufacturer's instruc-
tions. Densitometry was performed using ImageQuant TL software
(Amersham, Arlington Heights, IL, USA). Arbitrary densitometric units
for the protein of interest were normalized to the densitometric units
of α-tubulin.2.6. Statistical analyses
Unless otherwise indicated, each result in this paper is representa-
tive of at least three separate experiments.3. Results
3.1. Apoptogenic effect of 17α-E2 on human Jurkat T cell clones JT/Neo
and JT/Bcl-2
To elucidate the contribution of mitochondria-dependent apopto-
tic events to the apoptogenic activity of 17α-E2, we compared the
17α-E2-induced apoptotic sub-G1 peak, the mitochondrial membrane
potential (Δψm) loss, and apoptotic DNA fragmentation of Jurkat T
cells transfected with the empty vector (JT/Neo) with those of Jurkat
T cells transfected with the Bcl-2 expression vector (JT/Bcl-2). JT/Neo
cells following treatment with 17α-E2 at concentrations of 2.5 μM,
5.0 μM or 10 μM for 24 h exhibited an enhanced ratio of apoptotic
sub-G1 cells of 14.7%, 35.7% or 37.8%, respectively, whereas no en-
hancement of apoptotic sub-G1 cells was detected in JT/Bcl-2 cells
(Fig. 1A). Under these conditions, the fraction of G2/M phase cells
was signiﬁcantly elevated in both JT/Neo and JT/Bcl-2 cells following
17α-E2 treatment. When the Δψm loss of cells treated with 17α-E2
was measured through DiOC6 staining, the ratios of negative ﬂuo-
rescence in JT/Neo cells treated with 17α-E2 at concentrations of
2.5 μM, 5.0 μM, and 10 μMwere 18.0%, 32.4%, and 34.3%, respectively
(Fig. 1B). However, 17α-E2-induced Δψm loss was completely ab-
rogated in JT/Bcl-2 cells. Although 17α-E2-treated JT/Neo cells
clearly exhibited TUNEL-positive nuclei compared with control
cells, 17α-E2-treated JT/Bcl-2 cells failed to exhibit TUNEL-positive
cells (Fig. 1C).
These results indicate that the apoptogenic activity of 17α-E2 was
mediated by Δψm loss, which was prevented by the anti-apoptotic
protein Bcl-2 in Jurkat T cells. These results also indicate that the
G2/M-arrest that occurred prior to the induction of mitochondrial
damage and resultant apoptosis, was induced by a mechanism insen-
sitive to the anti-apoptotic activity of Bcl-2.3.2. Involvement of Bcl-2 phosphorylation, Mcl-1 phosphorylation,
Bim phosphorylation, Bak activation, and caspase-3 activation in
17α-E2-induced apoptosis in JT/Neo cells
To examine whether the Cdk1-mediated phosphorylation of Bcl-2
family proteins was upstream of 17α-E2-induced mitochondrial apo-
ptotic events, the phosphorylation status of Cdk1, Bcl-2, Mcl-1, Bcl-xL,
and Bimwas compared in JT/Neo and JT/Bcl-2 cells after 17α-E2 treat-
ment. While total Cdk1 levels were relatively stable, the levels of
Cdk1 phosphorylated at Tyr-15 appeared to decrease, and the levels
of Cdk1 phosphorylated at Thr-161 increased in JT/Neo and JT/Bcl-2
cells treated with 17α-E2 (Fig. 2A). At the same time, cyclin B1 levels
were upregulated in both cell types. Histone H1 phosphorylation,
which is catalyzed by Cdk1 during the G2/M phase [28], was en-
hanced in both cell types. The phosphorylation of histone H3 at
Ser-10 by aurora B kinase and the auto-phosphorylation of aurora A
kinase (ARK1) at Thr-288, both of which are known to be dictated
by Cdk1 during the G2/M phase [29,30], appeared to increase in both
cell types. The phosphorylation of Cdc25C at Thr-48, representing its
activation necessary for Cdk1 dephosphorylation at Tyr-15, was also
enhanced in both cell types. These results indicate that Cdk1was activat-
ed, and its enzymatic activity was sustained during 17α-E2-induced
G2/M arrest.
As shown in Fig. 2B, Bcl-2 phosphorylation at Thr-56 and Ser-70,
Mcl-1 phosphorylation at Ser-159 and/or Thr-163, and Bim (BimEL
and BimL) phosphorylation appeared to increase in JT/Neo and JT/
Bcl-2 cells following treatment with 17α-E2. However, Bcl-xL phos-
phorylation was not detected. Although the levels of Bcl-2, Bcl-xL,
Mcl-1, Bad, Bax, and Bid remained relatively constant, Bak levels
were enhanced ~3.4-fold in JT/Neo cells after 17α-E2 treatment (5–
10 μM). However, this 17α-E2-induced enhancement in Bak levels
was not observed in JT/Bcl-2 cells overexpressing Bcl-2. In addition,
Bak activation, as evidenced by its N-terminal conformational change
detected by a conformation-speciﬁc antibody (Ab-1), was observed
in JT/Neo cells, but not JT/Bcl-2 cells, treated with10 μM 17α-E2
(Fig. 2C). Under the same conditions, Bax activation was not observed
in either cell type (data not shown). In accordance with Bak acti-
vation in JT/Neo cells treated with 17α-E2, caspase-3 activation
through the proteolytic degradation of a 32-kDa proenzyme into a
17-kDa activated form, was detected in a dose-dependent manner.
In JT/Neo cells treated with 17α-E2, the cleavage of poly (ADP-
ribose) polymerase (PARP) into two fragments was detected along
with caspase-3 activation. However, the 17α-E2-induced activation
of caspase-3 and PARP degradation were completely abrogated in
JT/Bcl-2 cells.
Consequently, these results demonstrate that the 17α-E2-induced
apoptosis of Jurkat T cells was mediated by G2/M arrest accompany-
ing Cdk1 activation, phosphorylation of Bcl-2, Mcl-1 and Bim, up-
regulation of Bak levels, Bak activation, Δψm loss, and subsequent
caspsae-3 activation, leading to PARP degradation. These results also
indicate that 17α-E2-induced Cdk1 activation and phosphorylation of
Bcl-2, Mcl-1 and Bim were the upstream events of Bak activation and
mitochondria-dependent caspase activation, which could be targeted
by the anti-apoptotic function of Bcl-2.
3.3. Effect of hydroxyurea on 17α-E2-induced phosphorylation of Bcl-2,
Mcl-1, and Bim, Bak activation, mitochondrial damage, and subsequent
caspase-3 activation
To examine the dependency of 17α-E2-induced apoptotic events
on G2/M arrest, we examined the effect of hydroxyurea (OH-U),
which arrests cell cycle progression at the G1/S boundary [31,32],
on the 17α-E2-induced apoptotic signaling pathway. When JT/Neo
cells were treated with 1 mM OH-U for 20 h, 75.3% of the cells were
in the G1 phase, 15.8% of the cells were in the S phase, 5.3% of the
cells were in the G2/M phase, and only 3.8% of the cells were in the
Fig. 1. Change in cell cycle distribution (A), mitochondrial membrane potential (△Ψm) loss (B), and TUNEL-positive DNA fragmentation (C) in Jurkat T cells transfected with the
empty vector (JT/Neo) and Jurkat T cells transfected with the Bcl-2 expression vector (JT/Bcl-2) after treatment with 17α-E2. The cells were treated at a density of 5 × 105/ml with
indicated concentrations of 17α-E2 for 24 h. Cell cycle distribution and△Ψm loss were determined through ﬂow cytometric analysis of PI staining and DiOC6 staining, respectively.
DNA fragmentation analysis was performed using a TUNEL assay as described in Section 2. The scale bar represents a length of 10 μm in each of the images. A representative study is
shown; two additional experiments yielded similar results.
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Fig. 2. Western blot analyses of phosphorylated Cdk1 (Thr-161 and Tyr-15), Cdk1, cyclin B1, phosphorylated histone H1, histone H1, phosphorylated Cdc25C (Thr-48), Cdc25C,
phosphorylated aurora A (Thr-288), aurora A, phosphorylated histone H3 (Ser-10), histone H3, andα-tubulin (A), and phosphorylated Bcl-2 (Thr-56 and Ser-70), Bcl-2, phosphorylated
Mcl-1, Mcl-1, Bcl-xL, electrophoretic mobility retardation of Bim isoforms (BimEL and BimL), caspase-3, Bid, cleavage of PARP, and α-tubulin (B), and ﬂow cytometric analysis of Bak
activation (C) in JT/Neo and JT/Bcl-2 cells after treatment with 17α-E2. The cells were incubated at a density of 5 × 105/ml with the indicated concentrations of 17α-E2 for 24 h before
preparation of the cell lysates.Western blotting and Bak activation analysiswere performed as described in Section 2. Symbol:←*, phosphorylated formof Cdc25C. A representative study
is shown; two additional experiments yielded similar results.
2224 C.R. Han et al. / Biochimica et Biophysica Acta 1833 (2013) 2220–2232apoptotic sub-G1 phase, indicating that the majority of the cells were
arrested at the G1/S boundary (Fig. 3A).When JT/Neo cells were treated
with 10 μM17α-E2 for 20 h, 25.3% of the cells were in the sub-G1 phase,
with 9.7%, 10.5%, and 54.2% of the cells in the G1, S, and G2/M phases,
respectively. The 17α-E2-induced G2/M-arrest as well as apoptosis
was almost completely abrogated in the presence of OH-U with
68.4% of the cells in the G1 phase, 19.4% in the S phase, 6.3% in the
G2/M phase, and only 6.2% in the sub-G1 phase. In agreement with
the induced apoptotic sub-G1 peak, the 17α-E2-induced Δψm loss
was enhanced to a level of 22.3%; however, it was reduced to a
level of 7.2% in the presence of OH-U (Fig. 3B). Bak activation was
not observed when the cells, following treatment with 17α-E2, failed
to accumulate at the G2/M phase due to the concomitant presence of
OH-U (Fig. 3C).Western blot analyses also indicated that 17α-E2-induced activation
of Cdk1, histone H1 phosphorylation, Bcl-2 phosphorylation at Thr-56
and Ser-70, Mcl-1 phosphorylation at Ser-159 and/or Thr-163, Bim phos-
phorylation, aurora A auto-phosphorylation at Thr-288, histone H3 phos-
phorylation at Ser-10, Bak activation,Δψm loss, caspase-3 activation, and
PARP degradation were completely abrogated in the presence of OH-U
(Fig. 3D). At the same time, 17α-E2-induced Cdk1 dephosphorylation at
Tyr-15, Cdk1 phosphorylation at Thr-161, and Cdc25C phosphorylation
at Thr-48, all of which occurred as crucial events for the activation of
Cdk1 during the G2/M transition, were not observed.
These results show that the 17α-E2-induced outcomes including
Cdk1 activation, phosphorylation of Bcl-2,Mcl-1 andBim,Bak activation,
and mitochondria-dependent activation of caspase-3 were provoked as
a consequence of the G2/M arrest.
Fig. 3. Inhibitory effect of hydroxyurea (OH-U) on 17α-E2-induced G2/M arrest (A),△Ψm loss (B), Bak activation (C), and apoptotic change in phosphorylation of Cdk1 at Thr-161
and Tyr-15, Cdk1, phosphorylation of histone H1, histone H1, phosphorylation of Cdc25C at Thr-48, Cdc25C, phosphorylation of aurora A at Thr-288, aurora A, phosphorylation of
histone H3 at Ser-10, histone H3, phosphorylation of Bcl-2 at Thr-56 and Ser-70, Bcl-2, phosphorylation of Mcl-1, Mcl-1, electrophoretic mobility retardation of Bim isoforms,
caspase-3, cleavage of PARP, and α-tubulin (D) in JT/Neo cells. The cells were treated with 10 μM 17α-E2, 10 μM 17α-E2 plus 1 mM OH-U, or 1 mM OH-U for 20 h. Flow cytometric
analyses of cell cycle distribution, Δψm loss and Bak activation, andWestern blot analyses were performed as described in Section 2. Symbol:←*, phosphorylated form of Cdc25C. A
representative study is shown; two additional experiments yielded similar results.
2225C.R. Han et al. / Biochimica et Biophysica Acta 1833 (2013) 2220–22323.4. Effects of an aurora A kinase inhibitor, an aurora B kinase inhibitor,
and a Cdk1 inhibitor on 17α-E2-induced apoptotic events in JT/Neo cells
To elucidate the contribution ofmitotic kinases such as Cdk1, aurora
A kinase and aurora B kinase to 17α-induced phosphorylation of Bcl-2,Mcl-1 and Bim, we investigated the effect of the aurora A kinase inhib-
itor MLN8237, the aurora B kinase inhibitor AZD1152-HQPA, and the
Cdk1 inhibitor RO3306 on these 17α-E2-induced apoptotic events in
JT/Neo cells. As shown in Fig. 4A, the apoptotic sub-G1 peak was en-
hanced to a level of 49.1% following 17α-E2 treatment. The 17α-E2-
Fig. 4. Effect of aurora A kinase inhibitor MLN8237, aurora B kinase inhibitor AZD1152-HQPA, and Cdk1 inhibitor RO3306 on 17α-E2-induced G2/M-arrest (A), Δψm loss (B), and
Bak activation (C) in JT/Neo cells. After treatment with 10 μM 17α-E2 in the absence or in the presence of 12.5 nMMLN8237, 12.5 nM AZD1152-HQPA or 6 μM RO3306 for 20 h, the
cells were harvested. Flow cytometric analyses of cell cycle distribution, Δψm loss, and Bak activation were performed as described in Section 2. A representative study is shown;
two additional experiments yielded similar results.
2226 C.R. Han et al. / Biochimica et Biophysica Acta 1833 (2013) 2220–2232induced sub-G1 peak declined to a level of 14.7% after treatment with
6 μM RO3306, whereas the sub-G1 peak was not affected to a remark-
able level by either 12.5 nM MLN8237 or 12.5 nM AZD1152-HQPA.
This indicates that RO3306, but not MLN8237 and AZD1152-HQPA,
could suppress the 17α-E2-induced apoptotic sub-G1 peak by ~70%.
The 17α-E2-induced Δψm loss, which appeared to increase to a level
of 32.5%, was barely detected in the presence of RO3306; however,
the level was not signiﬁcantly altered in the presence of MLN8237 or
AZD1152-HQPA (Fig. 4B). When the effect of RO3306 on 17α-inducedBak activationwas investigated, RO3306 appeared to reduce Bak activa-
tion to basal levels (Fig. 4C).
Under these conditions, the individual inhibitors appeared to ef-
fectively inhibit their kinase targets, as evidenced by the data from
the Western blot analysis clearly exhibiting that RO3306, MLN8237,
and AZD1152-HQPA could suppress the 17α-E2-induced phosphory-
lation of histone H1, auto-phosphorylation of aurora A kinase at
Thr-288, and phosphorylation of histone H3 at Ser-10, respectively
(Fig. 5). When the 17α-E2-induced histone H1 phosphorylation was
Fig. 5. Western blot analyses of phosphorylated Cdk1 (Thr-161 and Tyr-15), Cdk1,
cyclin B1, phosphorylated histone H1, histone H1, phosphorylated Cdc25C (Thr-48),
Cdc25C, phosphorylated aurora A (Thr-288), aurora A, phosphorylated histone H3
(Ser-10), histone H3, phosphorylated Bcl-2 (Thr-56 and Ser-70), Bcl-2, phosphorylated
Mcl-1 (Ser-159/Thr-163), Mcl-1, electrophoretic mobility retardation of Bim isoforms,
caspase-3, and α-tubulin in JT/Neo cells after treatment with 17α-E2 in the absence or
presence of MLN8237, AZD1152-HQPA, or RO3306. After individual cell lysates were
prepared, Western blot analyses were performed as described in Section 2. Symbol:
←*, phosphorylated form of Cdc25C. A representative study is shown; two additional
experiments yielded similar results.
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caspase-3 activation, and PARP degradation were reduced to a barely
or undetectable level. The Cdk1 inhibitor RO3306 could also preventthe auto-phosphorylation of aurora A kinase at Thr-288 and the phos-
phorylation of histone H3 at Ser-10, indicating that 17α-E2-induced
activation of aurora A kinase and aurora B kinase was governed by
Cdk1. When the 17α-E2-induced auto-phosphorylation of aurora A
kinase was suppressed by MLN8237 or when the 17α-E2-induced
phosphorylation of histone H3 was suppressed by AZD1152-HQPA,
the 17α-E2-induced phosphorylation of histone H1, Bcl-2, Mcl-1 and
Bim, the activation of caspase-3, and the degradation of PARP were
sustained. Although JT/Neo cells treated with MLN8237 alone ex-
hibited an enhanced level of G2/M phase cells to a lesser extent com-
pared with the cells treated with RO3306 alone, the induction of the
apoptotic sub-G1 peak and Δψm loss was slightly more signiﬁcant.
In contrast to JT/Neo cells treated with RO3306 alone, there was a
detectable increase in the level of histone H1 phosphorylation after
treatment with MLN8237 alone. This raised the possibility that the
Cdk1 activity might be involved in MLN8237-induced apoptosis of
JT/Neo cells.
Consequently, these results show that although Cdk1, aurora A
kinase, and aurora B kinase were commonly activated in JT/Neo cells
treatedwith 17α-E2, the Cdk1 activitywas responsible for the phosphor-
ylation of Bcl-2,Mcl-1 and Bim leading to the activation ofmitochondria-
dependent caspase cascade.
3.5. Effect of 17α-E2 on the cellular microtubule network of JT/Neo and
JT/Bcl-2 cells
Tumor cells treated with microtubule-damaging drugs commonly
exhibit aberrant formation of the mitotic spindle, resulting in a block-
ade of mitosis and induction of apoptotic cell death [33–35]. To exam-
ine whether 17α-E2-induced G2/M arrest is associated with mitotic
spindle defects, the effect of 17α-E2 on the organization of the micro-
tubule network in JT/Neo and JT/Bcl-2 cells was investigated through
immunoﬂuorescence microscopy using an anti-α-tubulin antibody.
After JT/Neo and JT/Bcl-2 cells treated with 17α-E2 (10 μM) for vari-
ous time periods (0, 12 or 24 h) were adhered onto glass cover
slips, the microtubule network was visualized through immunoﬂuo-
rescence. Although the microtubule network in continuously growing
JT/Neo and JT/Bcl-2 cells showed a normal arrangement with the
majority of cells in the interphase, both cells exhibited an aberrant
bipolar array of microtubules after exposure to 17α-E2 for 12 and
24 h (Fig. 6A and B). In addition, DAPI staining revealed that while
some chromosomes in both cells treated with 17α-E2 were aligned
at the equator of the mitotic spindle, other chromosomes failed to
localize completely at the equator. Typical apoptotic bodies were ob-
served in JT/Neo cells treated with 17α-E2 for 24 h, but this apoptotic
feature was not observed in JT/Bcl-2 cells.
When 17α-E2-induced nuclear envelope breakdown was investi-
gated in JT/Neo and JT/Bcl-2 cells by immunoﬂuorescence microscopy
using the anti-lamin B antibody, both cell types arrested in the G2/M
phase by 17α-E2 exhibited no nuclear envelope (Fig. 7A and B). The
prometaphase is known to begin with a breakdown of the nuclear
envelope and continues until the sister chromatids attached to the
mitotic spindle are aligned at the spindle center [36]. These previous
and current results demonstrate that 17α-E2-induced mitotic arrest
was due to blockage at prometaphase because of mitotic spindle de-
fects and incomplete alignment of the chromosomes at the equatorial
plate. These results also suggest that the microtubule network may be
the primary intracellular target for the apoptotic activity of 17α-E2.
To examine whether the prometaphase arrest induced by 17α-E2
was reversible, JT/Bcl-2 cells treated with 17α-E2 (10 μM) for 20 h
were layered over FBS, centrifuged, washed three times with reagent-
free culture medium, and then incubated at 37 °C. As shown in Fig. 8A,
ﬂow cytometric analysis revealed that the continuously growing JT/
Bcl-2 cells were composed of 38.0% of G1 phase cells, 32.1% of S phase
cells, and 28.4% of G2/M phase cells. Treatment of JT/Bcl-2 cells with
17α-E2 blocked cell cycle progression at the G2/M phase efﬁciently;
Fig. 6. Effect of 17α-E2 on the organization of microtubule network in JT/Neo (A) and
JT/Bcl-2 (B) cells. After treatment with 10 μM 17α-E2 for various time periods (0, 12 or
24 h), the cells were adhered onto glass cover slips and ﬁxed with paraformaldehyde
for 30 min, permeabilized, incubated with mouse monoclonal anti-α-tubulin, and then
treated with Alexaﬂuor 488-conjugated goat anti-mouse immunoglobulin. Images were
obtained using a Carl Zeiss confocal laser scanning microscope. Symbols: sky-blue arrow-
head, apoptotic body; yellow arrowhead,metaphase chromosome congression; red/white
arrowhead, incomplete/complete chromosome congression at the metaphase plate. The
scale bar represents a length of 10 μm in each of the images. A representative study is
shown; two additional experiments yielded similar results.
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at the G1 phase, and 12.2% of the cells at the S phase. After releasing the
cells from blockage by incubating the cells in reagent-free culture medi-
um for up to 2 h, the level of G2/M phase cells was reduced in proportion
to the increase in the level of G1 phase cells. This suggests that the
17α-E2-induced mitotic arrest was reversible; the cells released from
the blocking point could continue progression through the cell cycle.
Supporting the ﬂow cytometry data, immunoﬂuorescence microscopy
also showed that the cells arrested at the prometaphase with mitotic
spindle defect and incomplete alignment of the chromosomes at the
equatorial plate could proceed to metaphase to complete mitosis in the
absence of 17α-E2 (Fig. 8B). Consequently, these results demonstrate
that the prometaphase arrest by 17α-E2 was a reversible event.We further examined whether 17α-E2 acts directly on microtubule
formation in the absence of cellular components using an in vitromicro-
tubule polymerization assay. When the commercially puriﬁed tubulin
polymerization reaction was started in the presence of GTP, a steady
state appeared to be reached after incubation for 30–40 min at 37 °C
(Fig. 9). Under the same conditions, 17α-E2 at a concentration of
10 μM appeared to inhibit tubulin polymerization, whereas the positive
control paclitaxel (10 μM) promoted tubulin polymerization, and the
negative control nocodazole (0.3 μM and 10 μM) suppressed tubulin
polymerization compared with the vehicle control (0.1% DMSO). These
results indicate that 17α-E2 (10 μM) was able to directly interfere
with microtubule formation.
4. Discussion
In this study, we have shown for the ﬁrst time that a pharmacolog-
ical dose (10 μM) of 17α-E2 is capable of inducing, prior to provoking
apoptosis, an aberrant bipolar microtubule array along with nuclear
envelope breakdown and incomplete alignment of the chromosomes
at the metaphase plate, all of which represent prometaphase arrest,
by direct inhibition of microtubule formation. The direct inhibitory
action of 17α-E2 on microtubule formation from tubulin subunits
was evidenced by the in vitro microtubule polymerization assay
exhibiting that 17α-E2 (10 μM) could suppress tubulin polymerization
in the absence of cellular components, as did nocodazole (0.3 μM).
This prometaphase arrest by17α-E2 was reversible; reversal was easily
accomplished by washing the cells and then incubating them in
reagent-free culture medium at 37 °C for 1–2 h. Because it has been
reported that Jurkat T cells do not express estrogen receptors (ERs)
[19], these previous and current data show that the reversible inhibition
ofmicrotubule formation, leading to prometaphase arrest, is the cellular
target of the apoptogenic activity of 17α-E2 in Jurkat T cells, which is
mediated in an ER-independent manner.
The M phase of the cell cycle can be subdivided into the prophase,
the prometaphase, the metaphase, the anaphase, and the telophase,
based on the microscopic characteristics of the microtubule organiza-
tion, chromosomes, and nuclear envelope [36,37]. When cells enter
into prophase from the G2 phase, the Cdk1 (Cdc2)/cyclin B complex,
which is held in an inactive state by phosphorylation at Thr-14 and
Tyr-15 mediated by the kinases Myt1 and Wee1, becomes activated
as a result of phosphorylation at Thr-161 by the Cdk-activating kinase
(Cak) as well as dephosphorylation at Thr-14 and Tyr-15 by the phos-
phatase Cdc25 [38,39]. Activated Cdk1 phosphorylates a large number
of substrates that are associatedwith nuclear envelope breakdown, cen-
trosome separation, spindle assembly, and chromosome condensation
[40]. In addition, activated Cdk1 should be inactivated through the
degradation of cyclin B by the anaphase-promoting complex (APC) to
progress from metaphase to anaphase. The sophisticated regulation
of Cdk1 activity is critical for the cell cycle, whereas prolonged Cdk1
activation resulting from an enforced arrest at the G2/M phase by
microtubule-targeting agents is known to act as an apoptotic mediator
[41–43]. In relation to the chemotherapy-mediated G2/M arrest accom-
panying apoptosis in tumor cells, two different molecular mechanisms,
the G2/M DNA damage checkpoint pathway and the mitotic spindle
checkpoint pathway, have been implicated [44–46]. Following exposure
to DNA-damaging drugs, cells can be arrested at the G2/M DNA damage
checkpoint by inactivating Cdk1/cyclin B through the action of Wee1
and Cdc25, and by p53-mediated transcriptional repression of cyclin B.
When the cells being treated with microtubule-damaging drugs fail to
align all chromosomes on the metaphase plate, the mitotic spindle
checkpoint becomes activated to prevent the onset of anaphase and
Cdk1/cyclin B is kept in an active state by inhibiting the role of APC. In
these contexts, we could exclude the involvement of the G2/M DNA
damage checkpoint in the 17α-E2-induced G2/M arrest and apoptosis,
because the Cdk1 activity appeared to be sustained during the G2/M
arrest by 17α-E2.
Fig. 7. Evidence for nuclear envelope breakdown in JT/Neo and JT/Bcl-2 cells treated with 17α-E2. After treatment of JT/Neo and JT/Bcl-2 cells with 10 μM 17α-E2 for 24 h, the
individual cells were adhered onto glass cover slips and ﬁxed with paraformaldehyde for 30 min, permeabilized, incubated with goat polyclonal anti-lamin B, and then treated
with TRITC-conjugated Alexaﬂuor 568-labeled donkey anti-goat immunoglobulin. Images were taken using a Carl Zeiss confocal laser scanning microscope. Symbols: yellow arrow-
head, metaphase chromosome congression; red/white arrowhead, incomplete/complete chromosome congression at themetaphase plate. The scale bar represents a length of 10 μm
in each of the images. A representative study is shown; two additional experiments yielded similar results.
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JT/Neo cells and JT/Bcl-2 cells showed that the 17α-E2-induced Bak
activation, Δψm loss and resultant activation of caspase-3, which
could be blocked by overexpression of Bcl-2, were crucial for the in-
duced apoptosis. The results also indicated that 17α-E2-induced
prometaphase arrest, Cdk1 activation, and phosphorylation of Bcl-2,
Mcl-1 and Bim were upstream of the Bcl-2-sensitive Bak activation
and mitochondrial apoptotic events. In the literature, the phosphory-
lation of anti-apoptotic Bcl-2 proteins such as Bcl-2, Bcl-xL, and Mcl-1
by Cdk1 appears to be crucial for coupling prolonged mitotic arrest to
microtubule inhibitor-induced apoptosis [43,47–49]. Recently, it has
been shown that Cdk1-dependent phosphorylation of Bim plays a
role in apoptosis induced by the well-known microtubule-targeting
drug taxol [50]. Bcl-2 phosphorylation is known to cause conforma-
tional changes that inactivate its anti-apoptotic function, leading tothe activation of Bax and/or Bak to provoke mitochondrial cyto-
chrome c release [35,47,51,52]. Mcl-1 phosphorylation has previously
been shown to mediate its destruction by the proteasome system to
render the cells more sensitive to apoptosis induced by microtubule
poisons [48,49]. Along with the 17α-E2-induced mitotic arrest, Bcl-2
phosphorylation at Thr-56 and Ser-70, Mcl-1 phosphorylation at
Ser-159 and/or Thr-163, and Bim phosphorylation were easily detected
by Western blot analyses. However, the 17α-E2-induced Mcl-1 phos-
phorylation was not accompanied by a remarkable reduction in Mcl-1
levels. The 17α-E2-induced Bcl-xL phosphorylation at Ser-62 was
detected only in Jurkat T cells overexpressing Bcl-xL (J/Bcl-xL; data
not shown). These previous and current results suggest that the phos-
phorylation of Bcl-2 and Bim rather than that of Bcl-xL and Mcl-1
might be the more critical apoptotic signals for 17α-E2-induced
apoptosis.
Fig. 8. Reversal of 17α-E2-induced G2/M arrest (A) and aberrant bipolarmicrotubule array (B) in JT/Bcl-2 cells. JT/Bcl-2 cells were cultured in the presence of 10 μM17α-E2 for 20 h to
arrest at the prometaphase, and the cells were released from the arrest by incubating in reagent-free culture medium for 1 and 2 h. Flow cytometric analysis of cell cycle distribution
was performed as described in Section 2. The organization of the microtubule network in the cells was visualized by immunoﬂuorescence as described in Fig. 6. Symbols: yellow
arrowhead, metaphase chromosome congression; red/white arrowhead, incomplete/complete chromosome congression at the metaphase plate. A representative study is shown;
two additional experiments yielded similar results.
Fig. 9. Inhibitory effect of 17α-E2 on tubulin polymerization in vitro. Commercially puriﬁed tubulins in reaction buffer were incubated at 37 °C in the presence of vehicle (0.1%
DMSO), 17α-E2 (10 μM), paclitaxel (10 μM, microtubule-polymerization agent), or nocodazole (0.3 μM and 10 μM, microtubule depolymerization agent). The kinetic reaction of
microtubule assembly was performed by measuring the absorbance at 340 nm with a spectrophotometry as described in Section 2. A representative study is shown; two additional
experiments yielded similar results.
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17α-E2-induced Cdk1 activation, phosphorylation of Bcl-2, Mcl-1
and Bim, activation of Bak, and mitochondria-dependent activation
of caspase-3 in Jurkat T cells, we investigated whether forced arrest of
cell cycle progression at the G1/S boundary by hydroxyurea (OH-U)
could abrogate the 17α-E2-induced apoptotic events. The mode of
action for OH-U is to inhibit ribonucleotide reductase, which converts
ribonucleotides to deoxyribonucleotides required for DNA synthesis,
thereby inhibiting entry into S phase in a variety of cells [31,32,53]. In
a previous study, using ﬂow cytometric analysis, we found that Jurkat
T cells treatedwith 10 μM17α-E2 and 1 mMOH-Uwere arrestedmain-
ly at the G1/S boundary with no induction of the apoptotic sub-G1 peak
[20]. While Jurkat T cells in the concomitant presence of 17α-E2 and
OH-U exhibited G1/S arrest rather than prometaphase arrest, none of
the apoptotic events including Cdk1 activation and phosphorylation of
Bcl-2,Mcl-1 and Bimwere induced. Consequently, these results conﬁrm
that the prometaphase arrest was the causal event of 17α-E2-induced
apoptotic cell death.
Because aurora A kinase and aurora B kinase appeared to be acti-
vated in addition to Cdk1 during 17α-E2-induced mitotic arrest and
apoptosis, and activation of aurora A kinase and aurora B kinase was
previously dictated by Cdk1 during the G2/M phase [29,30], the in-
volvement of these mitotic kinases in 17α-E2-induced phosphoryla-
tion of Bcl-2 family proteins and activation of the mitochondrial
apoptotic pathway were further investigated using validated inhibi-
tors for aurora A kinase, aurora B kinase, or Cdk1. In our experiments,
the minimum concentration of the Cdk1 inhibitor RO3306 required to
prevent the 17α-E2-induced phosphorylation of histone H1 in JT/Neo
cells was 6 μM (data not shown). Following treatment with 6 μM
RO3306 alone, JT/Neo cells exhibited G2/M arrest, reﬂecting success-
ful inhibition of the Cdk1 activity necessary for the G2/M transition.
Aurora A kinase inhibitor MLN8237 alone (12.5 nM), which appeared
to prevent the 17α-E2-induced activation of aurora A kinase, could
also mediate G2/M arrest, indicating a key role for the aurora A kinase
activity in the G2/M phase. In contrast, neither G2/M arrest nor apo-
ptotic sub-G1 peak was induced in JT/Neo cells following exposure
to aurora B kinase inhibitor AZD1152-HQPA alone (12.5 nM), which
was the lowest concentration to inhibit the 17α-E2-induced phos-
phorylation of histone H3. In JT/Neo cells, the 17α-E2-induced apo-
ptotic sub-G1 peak, phosphorylation of Bcl-2, Mcl-1 and Bim, Bak
activation, Δψm loss, and caspase-3 activation were diminished to a
barely or undetectable level by 6 μM RO3306, but not by 12.5 nM
MLN8237 or 12.5 nM AZD1152-HQPA. These results show that the
contribution of Cdk1 to mitotic arrest-dependent phosphorylation of
the Bcl-2 family proteins was a prerequisite for 17α-E2-induced acti-
vation of mitochondria-dependent apoptotic events.
The analysis of the immunoﬂuorescence microscopy of 17α-E2-
induced mitotic arrest in Jurkat T cells showed that the chromosomes
failed to congress at the metaphase plate along with an aberrant bipo-
lar array of microtubules and nuclear envelope breakdown. These
hallmarks of prometaphase arrest were more apparently observed
in JT/Bcl-2 cells compared with JT/Neo cells. The fact that 17α-E2-
induced prometaphase arrest could be reversible was also evident
in JT/Bcl-2 cells, because the prometaphase arrest was induced with-
out accompanying apoptotic cell death in JT/Bcl-2 cells.
5. Conclusions
In summary, our results show that the 17α-E2-induced apoptotic
signaling pathway leading to apoptotic DNA fragmentation in Jurkat
T cells proceeded through direct inhibition of microtubule formation
causing prometaphase arrest, prolonged activation of Cdk1, and sub-
sequent phosphorylation of Bcl-2, Mcl-1 and Bim. These microtubule
damage-mediated alterations could render the cellular context sus-
ceptible to the onset of mitochondria-dependent apoptosis by trigger-
ing Bak activation, Δψm loss, and resultant caspase cascade activation.These results also provide insight into themolecular and cellularmech-
anism underlying the pro-apoptotic role of the prolonged activation of
Cdk1 kinase in G2/M-arrested cells by a microtubule-inhibiting drug,
17α-E2.
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